Proteins and Peptides

06 Nov 2017 Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
02 Nov 2017 Biomarck Announces First Patients Treated in Phase 2 Clinical Trial of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)
01 Nov 2017 Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
31 Oct 2017 NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect
31 Oct 2017 Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
31 Oct 2017 Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
30 Oct 2017 Bayer Announces BAY94-9027 Biologics License Application Accepted by U.S. Food & Drug Administration
27 Oct 2017 Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25 Oct 2017 The first patient enrolled in the ReITIrate study evaluating immune tolerance induction with Elocta
24 Oct 2017 First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy
24 Oct 2017 Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
23 Oct 2017 Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting
23 Oct 2017 US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
19 Oct 2017 Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee
18 Oct 2017 BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
18 Oct 2017 Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
16 Oct 2017 Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients
13 Oct 2017 Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)
12 Oct 2017 Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
12 Oct 2017 First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP0274
11 Oct 2017 Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in Chemotherapy-Induced Neutropenia
11 Oct 2017 US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim
10 Oct 2017 Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
10 Oct 2017 China Biologic Receives Approval for Commercial Manufacturing of Human Fibrinogen
10 Oct 2017 Evolus Announces Presentations of Phase II and Phase III Data of PrabotulinumtoxinA

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top